| |
|
Product Name:
|
NIH 47885
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Paramyxoviridae, Respirovirus
Species: Human parainfluenza virus 3 (also referred to as human respirovirus 3)
Strain/Isolate: NIH 47885 (Laboratory-adapted Wash/47885/57)
|
|
Additional Information:
|
Human parainfluenza virus 3 (HPIV3) is an enveloped, negative-sense, single-stranded RNA virus of approximately 15000 base pairs, belonging to the family Paramyxoviridae.4,5,6 HPIV3 causes numerous potentially life-threatening respiratory illnesses in infancy and childhood, including pneumonia, croup, bronchitis and bronchiolitis.7 HPIV3 is lung-tropic and binds and replicates in the ciliated epithelial cells of the upper and lower respiratory tract.6,7 Seasonal outbreaks of all HPIV types (1 to 4) are responsible for up to 75% of croup cases in children worldwide.7,8
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney cells infected with HPIV3, NIH 47885.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-3233 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney cells (Vero E6; ATCC® CRL-1586™)
Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be 70% to 90% confluent
Incubation: 4 to 6 days at 37°C and 5% CO2
Cytopathic Effect: Cell rounding and sloughing
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Palermo, L. M., et al. “Features of Circulating Parainfluenza Virus Required for Growth in Human Airway.” mBio 7 (2016): doi: 10.1128/mBio.00235-16. PubMed: 26980833.
2. Galinski, M. S. “Annotated Nucleotide and Protein Sequences for Selected Paramyxoviridae.” In Kingsbury D.W. (ed.) The Paramyxoviruses. Plenum Press, New York (1991): 537-568.
3. Bailly, J. E., et al. “Sequence Determination and Molecular Analysis of Two Strains of Bovine Parainfluenza Virus Type 3 that are Attenuated for Primates.” Virus Genes 20 (2000): 173-182. PubMed: 10872880.
4. Ohsawa, K., et al. “Genetic Characterization of Parainfluenza Virus 3 Derived from Guinea Pigs.” J. Vet. Med. Sci. 60 (1998): 919-922. PubMed: 9764404.
5. Tappert, M. M., D. F. Smith and G. M. Air. “Fixation of Oligosaccharides to a Surface May Increase the Susceptibility to Human Parainfluenza Virus 1, 2, or 3 Hemagglutinin-Neuraminidase.” J. Virol. 85 (2011): 12146-12159. PubMed: 21917945.
6. Shil, N. K., et al. “Inflammasome Antagonism by Human Parainfluenza Virus Type 3 C Protein.” J. Virol. 92 (2018): doi: 10.1128/JVI.01776-17. PubMed: 29187536.
7. Branche, A. R. and A. R. Falsey. “Parainfluenza Virus Infection.” Semin. Respir Crit. Care Med. 37 (2016): 538-554. PubMed: 27486735.
8. Swierkosz, E. M., et al. “Isolation and Characterization of a Naturally Occurring Parainfluenza 3 Virus Variant.” J. Clin. Microbiol. 33 (1995): 1839-1841. PubMed: 7665656.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Human Parainfluenza Virus 3, NIH 47885, NR-3233.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|